Cite
High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
MLA
Peppone, Luke J., et al. “High‐dose Vitamin D to Attenuate Bone Loss in Patients with Prostate Cancer on Androgen Deprivation Therapy: A Phase 2 RCT.” Cancer (0008543X), vol. 130, no. 14, July 2024, pp. 2538–51. EBSCOhost, https://doi.org/10.1002/cncr.35275.
APA
Peppone, L. J., Kleckner, A. S., Fung, C., Puzas, J. E., Reschke, J. E., Culakova, E., Inglis, J., Kamen, C., Friedberg, J. W., Janelsins, M., Mustian, K., Heckler, C. E., & Mohile, S. (2024). High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT. Cancer (0008543X), 130(14), 2538–2551. https://doi.org/10.1002/cncr.35275
Chicago
Peppone, Luke J., Amber S. Kleckner, Chunkit Fung, J. Edward Puzas, Jennifer E. Reschke, Eva Culakova, Julia Inglis, et al. 2024. “High‐dose Vitamin D to Attenuate Bone Loss in Patients with Prostate Cancer on Androgen Deprivation Therapy: A Phase 2 RCT.” Cancer (0008543X) 130 (14): 2538–51. doi:10.1002/cncr.35275.